IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer

PURPOSE: To report toxicity and early survival data for IDEAL-CRT, a trial of dose-escalated concurrent chemoradiotherapy (CRT) for non-small cell lung cancer. PATIENTS AND METHODS: Patients received tumor doses of 63 to 73 Gy in 30 once-daily fractions over 6 weeks with 2 concurrent cycles of cispl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Radiat Oncol Biol Phys
Autors principals: Landau, David B., Hughes, Laura, Baker, Angela, Bates, Andrew T., Bayne, Michael C., Counsell, Nicholas, Garcia-Alonso, Angel, Harden, Susan V., Hicks, Jonathan D., Hughes, Simon R., Illsley, Marianne C., Khan, Iftekhar, Laurence, Virginia, Malik, Zafar, Mayles, Helen, Mayles, William Philip M., Miles, Elizabeth, Mohammed, Nazia, Ngai, Yenting, Parsons, Emma, Spicer, James, Wells, Paula, Wilkinson, Dean, Fenwick, John D.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier Science Inc 2016
Matèries:
Clinical Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4959796/
https://ncbi.nlm.nih.gov/pubmed/27296040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2016.03.031
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars